316 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
12 Mar 24
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
4:10pm
in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements … for the guidance period.
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
24 Jan 24
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
8:01am
statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based … ; the timing of the FDA’s review process and whether the FDA approves the PAS for the VAN; the outcome of the Company’s pending ANDA litigation related
8-K
EX-99.1
2m9tax35nu
11 Jan 24
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.1
q8v7ayu
14 Nov 23
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:10pm
424B3
wack7frmdg
5 Sep 23
Prospectus supplement
9:14pm
8-K
EX-99.1
v4szu
14 Aug 23
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
4:11pm
8-K
EX-10.1
4cv jvplx3
24 Jul 23
Heron Therapeutics Announces $30 Million Private Placement Financing
9:12am
8-K
EX-99.2
c9p1w1x7zlm2d9q
24 Jul 23
Heron Therapeutics Announces $30 Million Private Placement Financing
9:12am
8-K
EX-99.1
s4ius
24 Jul 23
Heron Therapeutics Announces $30 Million Private Placement Financing
9:12am
S-8
bt8g8ux ad
30 Jun 23
Registration of securities for employees
4:06pm
S-8
EX-99.1
injdaum nvyyqz9mokwh
30 Jun 23
Registration of securities for employees
4:06pm